The company's skin-based drug delivery systems are designed to enhance the delivery of almost any drug, old or new, and are minimally invasive, accurate, easy to use, and controllable. Nemaura Pharma collaborates with global pharmaceutical and biotech companies to bring superior delivery formulations and systems to patients. Founded in 2005, Nemaura has its headquarters and laboratory facilities in the UK and has secured patents in multiple countries. The company has an impressive pipeline of drugs under pre-clinical and clinical development, with an ANDA under review by the FDA for a Blockbuster drug, and a spin-out technology floated on the US Stock Exchange.